ADVM fundamentals
Key facts
Market capitalization79.67 MUSD
Basic EPS (TTM)−6.03USD
Founded2006
CEOLaurent Fischer
Websiteadverum.com
About
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
−2,740.00%
−2,680.00%
−2,620.00%
−2,560.00%
−2,500.00%
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
−33.00 M
−22.00 M
−11.00 M
0.00
11.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
ADVM does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company